- Home
- ATOS vs SNAL Comparison
ATOS vs SNAL Comparison
Compare ATOS & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATOS | SNAL |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.2M | 40.1M |
| IPO Year | 2010 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ATOS | SNAL |
|---|---|---|
| Price | $2.48 | $0.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | 104.6K | ★ 10.8M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 120.00 |
| EPS | N/A | ★ N/A |
| Revenue | $1,758.00 | ★ $81,225,622.00 |
| Revenue This Year | N/A | $15.53 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.53 | $0.34 |
| 52 Week High | $7.56 | $2.16 |
Technical Indicators
Market Signals| Indicator | ATOS | SNAL |
|---|---|---|
| Relative Strength Index (RSI) | 17.04 | 43.93 |
| Support Level | $0.63 | $0.66 |
| Resistance Level | $6.18 | $0.79 |
| Average True Range (ATR) | 0.25 | 0.07 |
| MACD | -0.24 | -0.03 |
| Stochastic Oscillator | 0.00 | 4.35 |
Price Performance
Historical ComparisonAbout ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.